REG - IXICO plc - Dementia collaboration

IXICOAnnouncement

26/01/2022 07:05

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220126:nRSZ5692Za&default-theme=true

RNS Number : 5692Z  IXICO plc  26 January 2022

IXICO plc

("IXICO" or the "Company")

 

Engagement in big data research dementia collaboration

 

IXICO continues its engagement in Dementias Platform UK as it enters its
second phase

 

IXICO plc (AIM: IXI), the data analytics company delivering insights in
neuroscience, announces that it has extended its commitment to Dementias
Platform UK (DPUK) as it enters its second phase. DPUK brings together the
best scientific minds and global leaders in the pharmaceutical industry to
find new ways of detecting, treating and preventing dementia.

 

DPUK fosters collaborations between academic centres of excellence and
industry experts to support research in three workstreams: (1) an expanded and
enhanced Data Portal to give researchers secure and rapid access to millions
of health research records; (2) the development of a Trials Delivery Framework
to match public volunteers to the right dementia studies; (3) An Experimental
Medicine Incubator to accelerate and de-risk the development of new
treatments.

IXICO will be an industry member and stakeholder in the DPUK partner forum,
working alongside 13 academic partners with expertise in dementia and big data
research such as University of Oxford, Cardiff University, University of
Cambridge and University of Edinburgh as well as pharma companies active in
dementia research such as AstraZeneca, GlaxoSmithKline, Janssen Pharmaceutica
NV and Araclon Biotech.

 

Prof John Gallacher, Director, DPUK, commented: "We are pleased to continue
the work with IXICO who are one of the founding partners of DPUK. Continuing
our mission to help scientists and pharma companies to achieve a world free of
dementia, I'm looking forward to working with IXICO to leverage novel imaging
measurements to improve clinical trial design and patient recruitment."

 

Dr Robin Wolz, Chief Scientific Officer at IXICO, commented: "It's exciting to
continue our engagement in Dementias Platform UK. As part of the second phase,
we are specifically planning to engage in the development of an efficient
Trials Delivery Framework. Applying our AI technology for the measurement of
brain volumes from MRI for the characterisation and stratification of
pre-clinical and early clinical dementia populations will support the
development of a trials delivery framework based on the concept of precision
recruitment. Implementing a precision medicine approach for patient selection
in those highly heterogeneous and challenging populations is expected to be a
key enabler to further extend recent successes in the development of treatment
in this area of high unmet need."

 

 

For further information please contact:

 

 IXICO plc                                                 +44 (0)20 3763 7498
 Giulio Cerroni, Chief Executive Officer

 Grant Nash, Chief Financial Officer

 Cenkos Securities PLC (Nominated adviser and sole broker)                  +44 (0)20 7397 8900
 Giles Balleny / Max Gould (Corporate Finance)
 Michael F Johnson / Russell Kerr (Sales)

 Walbrook PR Ltd     +44 (0)20 7933 8780

 Paul McManus / Lianne Applegarth /      IXICO@walbrookpr.com
 Alice Woodings

 

About IXICO

IXICO is dedicated to delivering insights in neuroscience. Our purpose is to
advance medicine and human health by turning data into clinically meaningful
information, providing valuable new insights in neuroscience and our goal is
to be a leading proponent of artificial intelligence in medical image
analysis. We will achieve this by developing and deploying breakthrough data
analytics, at scale, through our remote access technology platform, to improve
the return on investment in drug development and reduce risk and uncertainty
in clinical trials for our pharmaceutical clients.

 

More information is available on www.IXICO.com (http://www.IXICO.com)  and
follow us on Twitter @IXICOnews

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCUVAARUBUAUAR